PYC Therapeutics Ltd
ASX:PYC
PYC Therapeutics Ltd
Income from Continuing Operations
PYC Therapeutics Ltd
Income from Continuing Operations Peer Comparison
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
PYC Therapeutics Ltd
ASX:PYC
|
Income from Continuing Operations
-AU$21.7m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-23%
|
|
Immutep Ltd
ASX:IMM
|
Income from Continuing Operations
-AU$40.5m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-12%
|
|
Mesoblast Ltd
ASX:MSB
|
Income from Continuing Operations
-$73.1m
|
CAGR 3-Years
9%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
CSL Ltd
ASX:CSL
|
Income from Continuing Operations
$2.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Income from Continuing Operations
AU$30.2m
|
CAGR 3-Years
13%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Income from Continuing Operations
AU$5.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is PYC Therapeutics Ltd's Income from Continuing Operations?
Income from Continuing Operations
-21.7m
AUD
Based on the financial report for Dec 31, 2023, PYC Therapeutics Ltd's Income from Continuing Operations amounts to -21.7m AUD.
What is PYC Therapeutics Ltd's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
-23%
Over the last year, the Income from Continuing Operations growth was 12%. The average annual Income from Continuing Operations growth rates for PYC Therapeutics Ltd have been -20% over the past three years , -35% over the past five years , and -23% over the past ten years .